Kern County Hospital Authority
Kern County Hospital Authority was paid $48.08M by Medicaid between Jan 2018 and Dec 2024, across 436 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 18% of everything it billed.
33Billing provider infoKERN COUNTY HOSPITAL AUTHORITY
BAKERSFIELD, CA 93305
BAKERSFIELD, CA 93305
33aNPI1427176569assigned 03/27/2007
33bProvider typeCase Manager/Care Coordinator
28Total paid$48.08M
24GClaims1,737,440
24DCodes billed436
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Manager/Care Coordinator providers in California
Rank by total paid#40 of 435
Median peer was paid$2.89M
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 289,219 | $6.23M | |
| 2019 | 297,279 | $7.20M | |
| 2020 | 213,621 | $6.09M | |
| 2021 | 231,557 | $6.40M | |
| 2022 | 222,441 | $6.42M | |
| 2023 | 242,388 | $7.17M | |
| 2024incomplete | 240,935 | $8.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 337,799 | 264,226 | $8.59M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.3% | 91,891 | 87,533 | $3.04M |
| 0450 | Emergency room services | 5.1% | 33,368 | 28,728 | $2.44M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.0% | 64,595 | 61,845 | $2.41M |
| 59425 | 4.6% | 30,897 | 24,908 | $2.23M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 3,886 | 3,322 | $1.65M |
| Z7500 | 2.9% | 41,577 | 37,114 | $1.40M | |
| Z7502 | 2.8% | 36,067 | 35,500 | $1.35M | |
| Q3014 | Telehealth originating site facility fee | 2.5% | 42,870 | 38,964 | $1.20M |
| G0390 | Trauma response team associated with hospital critical care service | 2.4% | 481 | 448 | $1.18M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 2.4% | 989 | 930 | $1.17M |
| 0760 | 1.8% | 31,889 | 25,284 | $881K |
424 more codes
| 76818 | 1.7% | 13,426 | $796K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 11,762 | $668K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.4% | 48 | $661K |
| 0761 | 1.2% | 25,094 | $577K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 9,483 | $531K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,655 | $459K |
| 90674 | <1% | 13,717 | $429K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,631 | $424K |
| 90739 | <1% | 3,191 | $421K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16,617 | $409K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16,610 | $407K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,534 | $403K |
| 90715 | <1% | 11,752 | $396K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 6,617 | $385K |
| 90651 | <1% | 3,627 | $376K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14,274 | $366K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,413 | $359K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,874 | $291K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 776 | $289K |
| J3490 | Unclassified drugs | <1% | 15,515 | $270K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 11,156 | $257K |
| 80053 | Comprehensive metabolic panel | <1% | 29,122 | $244K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,272 | $241K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,107 | $232K |
| 0360 | <1% | 1,355 | $229K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,805 | $224K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,063 | $224K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,860 | $221K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 10,801 | $220K |
| 90677 | <1% | 2,130 | $213K | |
| 90732 | <1% | 1,564 | $207K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,699 | $207K |
| 99205 | Prolong outpt/office vis | <1% | 1,537 | $202K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,107 | $193K |
| 90686 | <1% | 13,073 | $190K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,211 | $185K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,120 | $177K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 8,676 | $171K |
| 90670 | <1% | 10,998 | $168K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,481 | $164K |
| 96127 | <1% | 23,575 | $160K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,987 | $157K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,882 | $155K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,277 | $152K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,464 | $141K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,866 | $141K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,036 | $137K |
| 86480 | <1% | 4,064 | $130K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 598 | $127K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 637 | $119K |
| 92551 | <1% | 11,184 | $116K | |
| 80061 | Lipid panel | <1% | 12,150 | $116K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,379 | $113K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,688 | $110K |
| 59430 | <1% | 1,395 | $109K | |
| 96415 | <1% | 2,147 | $103K | |
| 0510 | <1% | 4,510 | $99K | |
| 99173 | <1% | 21,848 | $99K | |
| 86331 | <1% | 6,465 | $97K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,062 | $96K |
| Z7610 | <1% | 13,668 | $96K | |
| 99606 | <1% | 4,195 | $94K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,178 | $92K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,445 | $88K |
| 0270 | <1% | 10,569 | $88K | |
| 86171 | <1% | 6,449 | $86K | |
| 0002A | <1% | 1,998 | $78K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 689 | $78K |
| 99381 | <1% | 1,262 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,635 | $76K |
| 96417 | <1% | 1,947 | $72K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,156 | $71K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,552 | $71K |
| 90680 | <1% | 7,462 | $69K | |
| 81002 | <1% | 28,606 | $69K | |
| 99385 | <1% | 517 | $66K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,514 | $65K |
| 0001A | <1% | 1,764 | $64K | |
| 99284 | Emergency room visit (serious) | <1% | 1,158 | $63K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,961 | $62K |
| 84439 | <1% | 9,110 | $60K | |
| 80074 | <1% | 1,711 | $60K | |
| 90633 | <1% | 6,458 | $60K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 941 | $57K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 139 | $56K |
| 90647 | <1% | 5,884 | $54K | |
| 90710 | <1% | 5,768 | $54K | |
| 81001 | <1% | 19,091 | $53K | |
| 99283 | Emergency room visit (moderate) | <1% | 552 | $52K |
| 73130 | <1% | 2,591 | $51K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,681 | $51K |
| 81025 | <1% | 13,637 | $51K | |
| 90750 | <1% | 269 | $50K | |
| 99607 | <1% | 2,273 | $50K | |
| 90723 | <1% | 5,236 | $48K | |
| 72100 | <1% | 2,196 | $47K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,150 | $46K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,244 | $46K |
| 83735 | <1% | 8,896 | $46K | |
| 0710 | <1% | 1,328 | $45K | |
| 90697 | <1% | 4,647 | $42K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 343 | $42K |
| 96156 | <1% | 487 | $41K | |
| 99188 | <1% | 1,773 | $38K | |
| 90734 | <1% | 3,717 | $37K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 303 | $36K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 27 | $35K |
| 73030 | <1% | 1,816 | $35K | |
| 73110 | <1% | 2,000 | $34K | |
| 86780 | <1% | 3,967 | $34K | |
| 96523 | <1% | 1,270 | $33K | |
| 80076 | <1% | 5,867 | $33K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 576 | $31K |
| 73562 | <1% | 1,590 | $30K | |
| 84100 | <1% | 8,188 | $29K | |
| 73630 | <1% | 1,673 | $29K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 722 | $29K |
| 90746 | <1% | 328 | $29K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 314 | $28K |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 3,870 | $28K |
| 73610 | <1% | 1,458 | $26K | |
| 99199 | Unlisted special service, procedure or report | <1% | 466 | $25K |
| 90649 | <1% | 2,461 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,471 | $25K |
| 82607 | <1% | 2,339 | $24K | |
| 99383 | <1% | 270 | $23K | |
| 0250 | <1% | 1,194 | $23K | |
| 90700 | <1% | 2,541 | $23K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 273 | $23K |
| 83690 | <1% | 4,147 | $23K | |
| 87081 | <1% | 4,844 | $22K | |
| 90696 | <1% | 2,400 | $22K | |
| 85730 | <1% | 4,730 | $22K | |
| 59025 | Fetal non-stress test | <1% | 1,307 | $22K |
| 92552 | <1% | 1,705 | $22K | |
| 0514 | <1% | 915 | $21K | |
| 82043 | <1% | 5,172 | $21K | |
| 82570 | <1% | 5,607 | $21K | |
| 80050 | General health panel | <1% | 237 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 332 | $20K |
| 73560 | <1% | 1,417 | $20K | |
| 92228 | <1% | 1,286 | $19K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 233 | $19K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,737 | $19K |
| 86235 | <1% | 1,420 | $19K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 64 | $19K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 826 | $19K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 400 | $19K |
| 85027 | <1% | 3,942 | $19K | |
| 86140 | <1% | 4,843 | $18K | |
| 85610 | <1% | 5,863 | $18K | |
| 90620 | <1% | 1,876 | $18K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,545 | $18K |
| 87186 | <1% | 2,928 | $18K | |
| 99243 | <1% | 345 | $18K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,745 | $18K |
| 0004A | <1% | 442 | $18K | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 27 | $17K |
| 83520 | <1% | 1,728 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,949 | $17K |
| 86803 | <1% | 1,572 | $16K | |
| 82378 | <1% | 1,159 | $16K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,760 | $15K |
| 87340 | <1% | 1,941 | $15K | |
| 90662 | <1% | 224 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,385 | $15K |
| 82728 | <1% | 1,518 | $14K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,440 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,874 | $14K |
| 72040 | <1% | 777 | $14K | |
| 99070 | <1% | 26,563 | $14K | |
| 86850 | <1% | 3,259 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,736 | $13K |
| 83655 | <1% | 1,728 | $13K | |
| 84702 | <1% | 1,216 | $13K | |
| 96367 | <1% | 303 | $12K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,660 | $12K |
| 88720 | <1% | 2,649 | $12K | |
| 84484 | <1% | 1,493 | $12K | |
| 86255 | <1% | 1,344 | $12K | |
| 86901 | <1% | 3,743 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,111 | $12K |
| 86762 | <1% | 999 | $12K | |
| 87077 | <1% | 1,955 | $11K | |
| 85652 | <1% | 5,520 | $11K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 643 | $11K |
| 96376 | <1% | 244 | $11K | |
| 83880 | <1% | 473 | $11K | |
| 86038 | <1% | 3,290 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 190 | $10K |
| 82948 | <1% | 2,900 | $10K | |
| 0054A | <1% | 256 | $10K | |
| 11981 | <1% | 415 | $10K | |
| 58100 | <1% | 350 | $9K | |
| 88307 | <1% | 200 | $9K | |
| 99384 | <1% | 93 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 646 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,362 | $9K |
| 85018 | <1% | 7,258 | $9K | |
| 76770 | <1% | 128 | $8K | |
| 86160 | <1% | 770 | $8K | |
| 74018 | <1% | 482 | $8K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 228 | $8K |
| 81003 | <1% | 3,954 | $8K | |
| 86900 | <1% | 2,635 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,365 | $7K |
| 83970 | <1% | 253 | $7K | |
| 83540 | <1% | 1,508 | $7K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,363 | $7K |
| 84153 | <1% | 713 | $7K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 479 | $7K |
| 87070 | <1% | 989 | $7K | |
| 83550 | <1% | 1,166 | $7K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 211 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 112 | $6K |
| 84703 | <1% | 1,171 | $6K | |
| 0072A | <1% | 153 | $6K | |
| 87210 | <1% | 1,954 | $6K | |
| 97802 | <1% | 229 | $6K | |
| 86431 | <1% | 1,451 | $6K | |
| 90678 | <1% | 54 | $6K | |
| 83605 | <1% | 665 | $6K | |
| 0052A | <1% | 143 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 278 | $5K |
| 72170 | <1% | 286 | $5K | |
| 90672 | <1% | 590 | $5K | |
| 0071A | <1% | 129 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 537 | $5K |
| 73120 | <1% | 393 | $5K | |
| 90656 | <1% | 536 | $5K | |
| 86317 | <1% | 924 | $5K | |
| 82950 | <1% | 1,285 | $5K | |
| 90694 | <1% | 61 | $5K | |
| 86162 | <1% | 640 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 831 | $4K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 298 | $4K |
| 11982 | <1% | 188 | $4K | |
| 73590 | <1% | 184 | $4K | |
| 82247 | <1% | 940 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 804 | $4K |
| 57454 | <1% | 129 | $4K | |
| 73090 | <1% | 149 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 468 | $4K |
| 86704 | <1% | 673 | $4K | |
| 87088 | <1% | 814 | $4K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 286 | $4K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 210 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 439 | $4K |
| 84999 | <1% | 390 | $4K | |
| H2000 | Comprehensive multidisciplinary evaluation | <1% | 42 | $4K |
| 72070 | <1% | 172 | $4K | |
| 99386 | <1% | 26 | $4K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 282 | $3K |
| 90480 | <1% | 86 | $3K | |
| 73502 | <1% | 129 | $3K | |
| 76536 | <1% | 62 | $3K | |
| 86592 | <1% | 1,412 | $3K | |
| 72202 | <1% | 140 | $3K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 690 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 75 | $3K |
| 82785 | <1% | 244 | $3K | |
| 76641 | <1% | 43 | $3K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 59 | $3K |
| 87338 | <1% | 274 | $3K | |
| 0320 | <1% | 86 | $3K | |
| 82550 | <1% | 520 | $2K | |
| 86146 | <1% | 121 | $2K | |
| 58300 | <1% | 137 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 407 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 15 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 39 | $2K |
| 86021 | <1% | 153 | $2K | |
| 90707 | <1% | 191 | $2K | |
| 86376 | <1% | 266 | $2K | |
| 0051A | <1% | 54 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,277 | $2K |
| P9011 | Blood, split unit | <1% | 745 | $2K |
| 84550 | <1% | 682 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 99 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 93 | $2K |
| 86706 | <1% | 475 | $2K | |
| 73080 | <1% | 99 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 91 | $2K |
| 86708 | <1% | 317 | $2K | |
| 90716 | <1% | 196 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 292 | $2K |
| 92134 | <1% | 87 | $2K | |
| 92015 | Determination of refractive state | <1% | 76 | $2K |
| 83615 | <1% | 440 | $2K | |
| 90681 | <1% | 204 | $2K | |
| 86003 | <1% | 384 | $2K | |
| Z7506 | <1% | 12 | $2K | |
| 87536 | <1% | 27 | $2K | |
| 83525 | <1% | 260 | $2K | |
| 82105 | <1% | 164 | $2K | |
| 86147 | <1% | 120 | $2K | |
| 86300 | <1% | 176 | $2K | |
| 76642 | <1% | 30 | $2K | |
| 90380 | <1% | 193 | $2K | |
| 91320 | <1% | 12 | $2K | |
| 80299 | <1% | 124 | $2K | |
| 96368 | <1% | 79 | $1K | |
| 99605 | <1% | 58 | $1K | |
| 84480 | <1% | 289 | $1K | |
| 87205 | <1% | 500 | $1K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 208 | $1K |
| 73100 | <1% | 102 | $1K | |
| 0517 | <1% | 51 | $1K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 35 | $1K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $1K |
| 69209 | <1% | 81 | $1K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 41 | $1K |
| 0515 | <1% | 52 | $1K | |
| 12001 | <1% | 53 | $1K | |
| 58301 | <1% | 49 | $1K | |
| 82248 | <1% | 399 | $1K | |
| 83001 | <1% | 82 | $1K | |
| 86812 | <1% | 84 | $1K | |
| 90381 | <1% | 137 | $1K | |
| 71020 | <1% | 39 | $1K | |
| 0124A | <1% | 26 | $1K | |
| 85613 | <1% | 116 | $970.01 | |
| 93971 | <1% | 28 | $953.21 | |
| 82746 | <1% | 88 | $952.66 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $946.52 |
| 82270 | <1% | 372 | $894.12 | |
| 76801 | <1% | 40 | $892.20 | |
| 90660 | <1% | 98 | $882.00 | |
| 97803 | <1% | 167 | $846.51 | |
| 82951 | <1% | 93 | $835.10 | |
| 99401 | <1% | 45 | $794.25 | |
| 72072 | <1% | 34 | $770.71 | |
| 84403 | <1% | 134 | $765.00 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 63 | $763.23 |
| Z7512 | <1% | 25 | $653.25 | |
| 86360 | <1% | 26 | $650.00 | |
| 99382 | <1% | 12 | $648.01 | |
| 86039 | <1% | 102 | $644.36 | |
| 82274 | <1% | 55 | $640.74 | |
| 82784 | <1% | 110 | $635.52 | |
| 72046 | <1% | 33 | $628.65 | |
| 12011 | <1% | 18 | $612.02 | |
| 0064A | <1% | 15 | $600.00 | |
| 99241 | <1% | 15 | $589.54 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $555.76 |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 68 | $551.64 |
| 90685 | <1% | 305 | $527.31 | |
| 83002 | <1% | 39 | $525.42 | |
| 82150 | <1% | 110 | $507.12 | |
| 84154 | <1% | 169 | $482.69 | |
| 96150 | <1% | 59 | $470.56 | |
| Z6400 | <1% | 39 | $470.34 | |
| 90648 | <1% | 52 | $468.00 | |
| 86705 | <1% | 52 | $454.39 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 113 | $452.11 |
| 84146 | <1% | 31 | $439.55 | |
| 10060 | <1% | 45 | $426.05 | |
| 96411 | <1% | 32 | $401.46 | |
| 86200 | <1% | 60 | $399.17 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 66 | $386.41 |
| 12002 | <1% | 12 | $371.97 | |
| 76870 | <1% | 13 | $365.76 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 27 | $361.26 |
| 84481 | <1% | 69 | $347.76 | |
| 99201 | <1% | 14 | $333.72 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 167 | $319.16 |
| 82977 | <1% | 138 | $311.18 | |
| 83516 | <1% | 38 | $293.64 | |
| 86580 | <1% | 63 | $292.63 | |
| 86695 | <1% | 38 | $288.22 | |
| 86696 | <1% | 38 | $288.22 | |
| V5008 | Hearing screening | <1% | 13 | $285.54 |
| 87625 | <1% | 14 | $285.02 | |
| 17110 | <1% | 13 | $281.60 | |
| 88142 | <1% | 84 | $277.32 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 377 | $268.16 |
| 86304 | <1% | 34 | $264.00 | |
| 90713 | <1% | 28 | $252.00 | |
| 84156 | <1% | 101 | $231.79 | |
| 86800 | <1% | 46 | $225.31 | |
| 82952 | <1% | 76 | $210.22 | |
| 81000 | <1% | 181 | $204.07 | |
| 11983 | <1% | 12 | $201.60 | |
| 99001 | <1% | 150 | $200.07 | |
| 73000 | <1% | 12 | $189.68 | |
| 29125 | <1% | 13 | $189.60 | |
| 86403 | <1% | 18 | $184.60 | |
| 86671 | <1% | 13 | $174.09 | |
| 87902 | <1% | 13 | $160.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 15 | $159.85 |
| 88304 | <1% | 13 | $159.84 | |
| 84436 | <1% | 35 | $154.00 | |
| 90473 | <1% | 526 | $153.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 23 | $137.33 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 51 | $120.78 |
| 90744 | <1% | 13 | $117.00 | |
| 84402 | <1% | 17 | $102.00 | |
| 84165 | <1% | 19 | $98.56 | |
| 82272 | <1% | 59 | $88.06 | |
| 80143 | <1% | 12 | $86.78 | |
| 85014 | <1% | 41 | $85.35 | |
| 87040 | <1% | 16 | $76.42 | |
| 94060 | <1% | 12 | $62.02 | |
| 82010 | <1% | 13 | $54.61 | |
| 88312 | <1% | 13 | $52.52 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 15 | $47.26 |
| 82565 | <1% | 13 | $40.86 | |
| 87147 | <1% | 12 | $28.82 | |
| 3079F | 0% | 3,466 | $0.00 | |
| 3074F | 0% | 6,026 | $0.00 | |
| 3075F | 0% | 1,302 | $0.00 | |
| 0370 | 0% | 20 | $0.00 | |
| 90673 | 0% | 124 | $0.00 | |
| 3080F | 0% | 30 | $0.00 | |
| 2023F | 0% | 27 | $0.00 | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | 0% | 27 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 13 | $0.00 |
| 3078F | 0% | 5,476 | $0.00 | |
| H1002 | Prenatal care, at risk enhanced service; care coordination | 0% | 37 | $0.00 |
| 3077F | 0% | 797 | $0.00 | |
| 80361 | 0% | 555 | $0.00 | |
| J1750 | Injection, iron dextran, 50 mg | 0% | 26 | $0.00 |
| 92133 | 0% | 13 | $0.00 | |
| 90661 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCANTU, ANDY (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Kern County Hospital Authority | Bakersfield, CA | $6.70M |
| Dignity Health | Bakersfield, CA | $733K |
| Kern County Hospital Authority | Bakersfield, CA | $241K |
| Kern County Hospital Authority | Bakersfield, CA | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.